摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-羟基-2-萘丙酸 | 553-39-9

中文名称
6-羟基-2-萘丙酸
中文别名
——
英文名称
3-(6-hydroxy-2-naphthyl)propionic acid
英文别名
3-(6-hydroxy-[2]naphthyl)-propionic acid;3-(6-Hydroxy-[2]naphthyl)-propionsaeure;6-hydroxy-2-naphthalenepropanoic acid;3-(6-hydroxy-2-naphthyl)-propionic acid;allenolic acid;3-(6-hydroxynaphthalen-2-yl)propanoic acid
6-羟基-2-萘丙酸化学式
CAS
553-39-9
化学式
C13H12O3
mdl
——
分子量
216.236
InChiKey
NHGXZNWPADXVOA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    180-181°
  • 沸点:
    316.65°C (rough estimate)
  • 密度:
    1.1652 (rough estimate)
  • LogP:
    2.330 (est)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    57.5
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2918199090

SDS

SDS:0fc21b7b920dd64bc17110fcd1b8bc48
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-羟基-2-萘丙酸辅酶 A氯甲酸乙酯碳酸氢钠三乙胺 作用下, 以 四氢呋喃 为溶剂, 反应 0.17h, 生成
    参考文献:
    名称:
    脂肪酸代谢的荧光形态底物:哺乳动物中链酰基辅酶A脱氢酶的高灵敏度探针。
    摘要:
    DOI:
    10.1002/anie.200502675
  • 作为产物:
    描述:
    6-溴-2-萘酚 在 bis-triphenylphosphine-palladium(II) chloride 、 palladium on activated charcoal 氢气碳酸氢钠 作用下, 以 四氢呋喃N-甲基吡咯烷酮 为溶剂, 130.0 ℃ 、275.79 kPa 条件下, 反应 16.5h, 生成 6-羟基-2-萘丙酸
    参考文献:
    名称:
    脂肪酸代谢的荧光形态底物:哺乳动物中链酰基辅酶A脱氢酶的高灵敏度探针。
    摘要:
    DOI:
    10.1002/anie.200502675
点击查看最新优质反应信息

文献信息

  • Niacin receptor agonists, compositions containing such compounds and methods of treatment
    申请人:Raghavan Subharekha
    公开号:US20060293364A1
    公开(公告)日:2006-12-28
    The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
    本发明涵盖了Formula I的化合物: 以及其药用可接受的盐和水合物,用于治疗动脉粥样硬化、血脂异常等疾病。药物组合物和使用方法也包括在内。
  • Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
    申请人:Bezwada Rao S.
    公开号:US20120035259A1
    公开(公告)日:2012-02-09
    The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.
    本发明提供了一氧化氮(NO)和可选的药物释放的大分子和寡聚物,其中药物分子和一氧化氮释放部分通过可吸收的大分子或可水解降解的寡聚物链连接,并且大分子或寡聚物由来自诸如乙醇酸、乳酸、己内酰胺和对二恶烷等安全且生物相容的分子的重复单元组成。此外,本发明还涉及从一氧化氮和/或药物分子释放的大分子或寡聚物控制释放一氧化氮(NO)。此外,本发明还涉及包含本发明的一氧化氮和药物释放大分子和寡聚物的医疗器械、医疗器械涂层和治疗方法。
  • ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES
    申请人:Bezwada Biomedical, LLC
    公开号:US20140142199A1
    公开(公告)日:2014-05-22
    The present invention relates to the discovery of a new class of hydrolysable isocyanates, hydrolysable branched polyols and branched absorbable polyesters and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, stents, highly porous foam, reticulated foam, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers can have a controlled hydrolytic degradation profile.
    本发明涉及一种新型可水解异氰酸酯、可水解支链多元醇及其制备的支链可吸收聚酯和聚氨酯的发现。由此得到的可吸收聚合物可用于药物输送、支架、高孔隙率泡沫、网状泡沫、组织工程、组织粘合剂、防止粘连、骨蜡制剂、医疗设备涂层、表面改性剂以及其他可植入医疗设备。此外,这些可吸收聚合物可以具有受控的水解降解特性。
  • Methods of treating hormone-related conditions using cyclothiocarbamate derivatives
    申请人:Wyeth
    公开号:US20040006060A1
    公开(公告)日:2004-01-08
    The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I or formula II, or tautomers thereof, in a regimen which involves delivering one or more of a selective estrogen receptor modulator, wherein formula I is: 1 and wherein R 1 -R 5 and Q 1 are defined as described herein. Methods of providing hormone replacement therapy and for treating carcinomas, dysfunctional bleeding, uterine leiomyomata, endometriosis, and polycystic ovary syndrome is provided which includes delivering a compound of formula I and a selective estrogen receptor modulator are also described.
    本发明提供了一种诱导避孕的方法,包括向女性投递包含公式I或公式II的化合物或其互变异构体的组合物,并且涉及的给药方案包括投递一种或多种选择性雌激素受体调节剂,其中公式I是:1,其中R1-R5和Q1如本文所述定义。本发明还提供了一种提供激素替代疗法以及治疗癌变、功能失调性出血、子宫肌瘤、子宫内膜异位症和多囊卵巢综合征的方法,包括投递公式I的化合物和一种选择性雌激素受体调节剂,这些方法也在此描述。
  • Functionalized drugs and polymers derived therefrom
    申请人:Bezwada S. Rao
    公开号:US20060172983A1
    公开(公告)日:2006-08-03
    Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.
    从中选择的化合物:其中DRUG-OH,DRUG-COOH和DRUG-NH2是生物活性化合物;每个X独立地从—CH2COO—(乙二酸基团),—CH(CH3)COO—(乳酸基团),—CH2CH2OCH2COO—(二氧杂环己酮基团),—CH2CH2CH2CH2CH2COO—(己内酯基团),—(CH2)yCOO—中选择,其中y为2-4或6-24和—(CH2CH2O)zCH2COO—,其中z为2-24;每个Y独立地从—COCH2O—(乙二酸酯基团),—COCH(CH3)O—(乳酸酯基团),—COCH2OCH2CH2O—(二氧杂环己酮酯基团),—COCH2CH2CH2CH2CH2O—(己内酯酯基团),—CO(CH2)mO—,其中m为2-4或6-24和—COCH2O(CH2CH2O)n—,其中n为2-24;R′为氢,苄基或烷基,烷基可以是直链或支链;p为1-6。还披露了多功能化合物和药物二聚体、寡聚体和聚合物。
查看更多